Press releases
November, 05, 2010
Sanofi-aventis partners in European Atrial Fibrillation Research Consortium
Consortium awarded European Union grant for 5 years of Atrial Fibrillation research.
Paris, France – November 5, 2010 – Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced today that it is a partner in a new multidisciplinary atrial fibrillation research consortium, the “European Network for Translational research in Atrial Fibrillation” (EUTRAF), which has been awarded a €12 million grant to engage in atrial fibrillation (AF)i research. The European consortium is commencing a five-year research project with the objectives of providing highly interactive research with a variety of expertise to improve management of AF including diagnosis, prevention and treatment.
“Sanofi-aventis is committed to further advancing AF patient care and delighted to do so in collaboration with a network of highly respected scientific institutions and recognised clinical experts in the field of AF,” said Marc Cluzel MD, PhD, Executive Vice President, Research and Development, sanofi-aventis. “We are proud to provide sanofi-aventis R&D expertise and to contribute new candidate molecules to the network. Sanofi-aventis’ pioneering research in AF spans several decades and has led to innovations such as amiodarone, and dronedarone.”
Paris, France – November 5, 2010 – Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced today that it is a partner in a new multidisciplinary atrial fibrillation research consortium, the “European Network for Translational research in Atrial Fibrillation” (EUTRAF), which has been awarded a €12 million grant to engage in atrial fibrillation (AF)i research. The European consortium is commencing a five-year research project with the objectives of providing highly interactive research with a variety of expertise to improve management of AF including diagnosis, prevention and treatment.
“Sanofi-aventis is committed to further advancing AF patient care and delighted to do so in collaboration with a network of highly respected scientific institutions and recognised clinical experts in the field of AF,” said Marc Cluzel MD, PhD, Executive Vice President, Research and Development, sanofi-aventis. “We are proud to provide sanofi-aventis R&D expertise and to contribute new candidate molecules to the network. Sanofi-aventis’ pioneering research in AF spans several decades and has led to innovations such as amiodarone, and dronedarone.”
Consortium awarded European Union grant for 5 years of Atrial Fibrillation research.
Paris, France – November 5, 2010 – Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced today that it is a partner in a new multidisciplinary atrial fibrillation research consortium, the “European Network for Translational research in Atrial Fibrillation” (EUTRAF), which has been awarded a €12 million grant to engage in atrial fibrillation (AF)i research. The European consortium is commencing a five-year research project with the objectives of providing highly interactive research with a variety of expertise to improve management of AF including diagnosis, prevention and treatment.
“Sanofi-aventis is committed to further advancing AF patient care and delighted to do so in collaboration with a network of highly respected scientific institutions and recognised clinical experts in the field of AF,” said Marc Cluzel MD, PhD, Executive Vice President, Research and Development, sanofi-aventis. “We are proud to provide sanofi-aventis R&D expertise and to contribute new candidate molecules to the network. Sanofi-aventis’ pioneering research in AF spans several decades and has led to innovations such as amiodarone, and dronedarone.”
Paris, France – November 5, 2010 – Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced today that it is a partner in a new multidisciplinary atrial fibrillation research consortium, the “European Network for Translational research in Atrial Fibrillation” (EUTRAF), which has been awarded a €12 million grant to engage in atrial fibrillation (AF)i research. The European consortium is commencing a five-year research project with the objectives of providing highly interactive research with a variety of expertise to improve management of AF including diagnosis, prevention and treatment.
“Sanofi-aventis is committed to further advancing AF patient care and delighted to do so in collaboration with a network of highly respected scientific institutions and recognised clinical experts in the field of AF,” said Marc Cluzel MD, PhD, Executive Vice President, Research and Development, sanofi-aventis. “We are proud to provide sanofi-aventis R&D expertise and to contribute new candidate molecules to the network. Sanofi-aventis’ pioneering research in AF spans several decades and has led to innovations such as amiodarone, and dronedarone.”
Latest videos
The True Cost of Atrial Fibrillation
Latest Congress Announcement
ESC Congress 2011
This year, ESC Congress goes to Paris. The event is the year’s “Rendez-vous” for everybody involved in Cardiovascular Medicine, from clinical practitioners to basic scientists, epidemiologists, nurses, technicians, health care industry, opinion leaders and policy makers from around the world.
Paris, France.
Paris, France.